by | Jul 4, 2024 | Publications
Mol Biomed. 2024 Jul 4;5(1):25. doi: 10.1186/s43556-024-00188-w. ABSTRACT Multiple myeloma (MM) is the second most common hematological malignancy of plasma cells, characterized by osteolytic bone lesions, anemia, hypercalcemia, renal failure, and the accumulation of...
by | Jul 4, 2024 | Publications
Nat Rev Clin Oncol. 2024 Jul 3. doi: 10.1038/s41571-024-00913-y. Online ahead of print. ABSTRACT A better understanding of the roles of the adaptive and innate immune systems in the oncogenesis of cancers including multiple myeloma (MM) has led to the development of...
by | Jul 4, 2024 | Publications
Mutat Res. 2024 Jun 18;829:111869. doi: 10.1016/j.mrfmmm.2024.111869. Online ahead of print. ABSTRACT BACKGROUND: Multiple myeloma cancer stem cells (MMSC) have been considered as the leading cause of multiple myeloma (MM) drug resistance and eventual relapse,...
by | Jul 4, 2024 | Publications
Rinsho Ketsueki. 2024;65(6):492-497. doi: 10.11406/rinketsu.65.492. ABSTRACT A 69-year-old man presented with lumbago and was diagnosed with multiple myeloma (IgD-λ type, R-ISS stage II) with bone-destructive lesions in the lumbar spine and sacrum. Chromosome analysis...
by | Jul 4, 2024 | Publications
Rinsho Ketsueki. 2024;65(6):547-557. doi: 10.11406/rinketsu.65.547. ABSTRACT B-cell maturation antigen (BCMA)-targeting therapy is the most common approach to immunotherapy and cellular therapy for multiple myeloma (MM). Three major agents, CAR-T cells, bispecific...
by | Jul 3, 2024 | Publications
Hematology. 2024 Dec;29(1):2365096. doi: 10.1080/16078454.2024.2365096. Epub 2024 Jul 3. ABSTRACT BACKGROUND/PURPOSE: The treatment landscape of relapsed/refractory multiple myeloma (RRMM) is rapidly evolving in Taiwan. The present study aimed to assess the treatment...
